Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,814,336
  • Shares Outstanding, K 109,276
  • Annual Sales, $ 6,711 M
  • Annual Income, $ 2,444 M
  • 60-Month Beta 1.20
  • Price/Sales 6.56
  • Price/Cash Flow 18.13
  • Price/Book 5.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 5.24
  • Number of Estimates 1
  • High Estimate 5.24
  • Low Estimate 5.24
  • Prior Year 3.98
  • Growth Rate Est. (year over year) +31.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
388.49 +1.68%
on 03/25/19
442.00 -10.63%
on 03/04/19
-25.38 (-6.04%)
since 02/25/19
3-Month
339.13 +16.47%
on 12/26/18
442.00 -10.63%
on 03/04/19
+54.36 (+15.96%)
since 12/24/18
52-Week
281.89 +40.13%
on 05/09/18
442.00 -10.63%
on 03/04/19
+73.71 (+22.94%)
since 03/23/18

Most Recent Stories

More News
Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Mastercard Incorporated (NYSE:MA),...

HAL : 28.24 (-1.71%)
MA : 230.42 (-0.15%)
KEYS : 84.78 (+0.02%)
LLY : 129.87 (+1.22%)
REGN : 395.00 (+0.82%)
WNC : 13.14 (-0.08%)
Watch for Regeneron Pharm to Potentially Rebound After Falling 1.72% Yesterday

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $398.20 to a high of $403.02. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of...

REGN : 395.00 (+0.82%)
Atopic Dermatitis Market Highest Growth in Healthcare with Size, Share, Price Trend, Foreseen by 2023

VRX.TO : 30.80 (-3.33%)
ANAC : 99.06 (-0.14%)
AGN : 146.34 (-1.98%)
ALPMF : 15.6300 (+1.26%)
NVS : 93.31 (-0.12%)
REGN : 395.00 (+0.82%)
PFE : 41.89 (+0.10%)
BMY : 47.49 (-1.39%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 53.88 (+0.47%)
IBB : 108.32 (+0.14%)
ALNY : 84.17 (-0.41%)
QGEN : 39.77 (+0.89%)
REGN : 395.00 (+0.82%)
XBI : 87.99 (+0.15%)
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

BAYRY : 16.1800 (-2.74%)
REGN : 395.00 (+0.82%)
AMGN : 186.59 (-0.06%)
SNY : 43.95 (-0.70%)
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.

AZN : 42.55 (-0.09%)
INO : 3.62 (unch)
RHHBY : 33.8300 (+0.21%)
REGN : 395.00 (+0.82%)
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease

Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack

REGN : 395.00 (+0.82%)
10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run

Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.

NFLX : 366.23 (+1.45%)
ULTA : 336.67 (+1.86%)
ABMD : 313.22 (-3.09%)
INCY : 86.02 (+0.80%)
WCG : 240.73 (-0.46%)
REGN : 395.00 (+0.82%)
ALGN : 271.02 (+0.52%)
URI : 111.12 (+0.14%)
SPY : 279.04 (-0.08%)
BKNG : 1,752.39 (+1.79%)
AMZN : 1,774.26 (+0.54%)
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

Key highlights of the past week are regulatory and pipeline developments.

CELG : 87.92 (-0.26%)
VRTX : 183.85 (+1.28%)
ZFGN : 2.69 (-5.28%)
AMAG : 12.10 (-0.49%)
REGN : 395.00 (+0.82%)
SNY : 43.95 (-0.70%)
Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down

Inovio Pharmaceuticals (INO) reports results for fourth quarter of 2018 wherein loss and revenues both miss estimates.

AZN : 42.55 (-0.09%)
INO : 3.62 (unch)
RHHBY : 33.8300 (+0.21%)
REGN : 395.00 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 402.82
1st Resistance Point 398.91
Last Price 395.00
1st Support Level 389.79
2nd Support Level 384.58

See More

52-Week High 442.00
Last Price 395.00
Fibonacci 61.8% 380.84
Fibonacci 50% 361.95
Fibonacci 38.2% 343.05
52-Week Low 281.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar